Johan Isaksson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johan Isaksson has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Gunnar Wagenius
5 shared publicationsAnders Berglund
4 shared publications- Linda Willén
Center for Research and Development, Uppsala University/Region Gävleborg, Gävle, Sweden
4 shared publications - Mats Lambe
Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
4 shared publications - Stefan Bergström
Center for Research and Development, Uppsala University/Region Gävleborg, Gävle, Sweden
3 shared publications - Anders Berglund
EpiStat AB, Uppsala, Sweden
2 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by Elsevier in Cancer Letters
- Vol. 658, 218728
Vascular leakage in non-small cell lung cancer is associated with immune evasion and poor response to immunotherapy
- 22 July 2026
- Published by Elsevier in Cancer Letters
- Vol. 658, 218728
Open AccessVascular leakage in non-small cell lung cancer is associated with immune evasion and poor response to immunotherapy
- Open Access
- 17 April 2026
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 65, 301-305
Multidisciplinary team meetings for lung cancer in the Nordic countries: results from a Nordic survey
- 17 April 2026
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 65, 301-305
Open AccessMultidisciplinary team meetings for lung cancer in the Nordic countries: results from a Nordic survey
- Open Access
- 6 January 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 47, 100703
Current opinions on lung cancer screening in the Nordic countries: A survey-based study
- 6 January 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 47, 100703
Open AccessCurrent opinions on lung cancer screening in the Nordic countries: A survey-based study
- Open Access
- 4 June 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 734-741
Comparative study of lung cancer care and survival outcomes across the Nordic countries
Background: Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. Despite societal, economic and genetic similarities, 5-year age-standardized relative survival rate is lower in Finland compared to the other Nordic countries. Previous studies have identified discrepancies in LC guidelines, but research on actual care practices remains limited. We aim to address this knowledge gap by conducting a comprehensive examination of the current care practices for LC patients in the Nordic countries. Methods: We employed a non-interventional, prospective study design. We conducted an expert workshop involving LC specialists from Finland to formulate relevant questions for a structured survey. This survey was distributed to healthcare professionals (HCPs) across Nordic hospitals and primary care units. The survey results were then analyzed, and a follow-up Nordic LC expert workshop was held to identify the most relevant factors potentially influencing LC survival outcomes. Results: Four key differences in care practices between Finland and other Nordic countries were identified: (1) resources available in primary care units, (2) waiting times in primary care, (3) availability of novel treatments and (4) tracking of LC survival and mortality outcomes by the hospital. Finland has the lowest access to computed tomography (CT) from primary care, longest waiting times in primary care, and lacks a national outcome tracking system. Some medical doctors in Finland and Iceland highlighted observed limitations in specific cases involving access to neoadjuvant immunotherapy and chemotherapy. Interpretation: Several factors unrelated to specialized LC care are likely contributing to poorer 5-year survival rates for LC in Finland. These findings may be applicable to other healthcare systems as well.
- 4 June 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 734-741
Open AccessComparative study of lung cancer care and survival outcomes across the Nordic countries
Background: Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. Despite societal, economic and genetic similarities, 5-year age-standardized relative survival rate is lower in Finland compared to the other Nordic countries. Previous studies have identified discrepancies in LC guidelines, but research on actual care practices remains limited. We aim to address this knowledge gap by conducting a comprehensive examination of the current care practices for LC patients in the Nordic countries. Methods: We employed a non-interventional, prospective study design. We conducted an expert workshop involving LC specialists from Finland to formulate relevant questions for a structured survey. This survey was distributed to healthcare professionals (HCPs) across Nordic hospitals and primary care units. The survey results were then analyzed, and a follow-up Nordic LC expert workshop was held to identify the most relevant factors potentially influencing LC survival outcomes. Results: Four key differences in care practices between Finland and other Nordic countries were identified: (1) resources available in primary care units, (2) waiting times in primary care, (3) availability of novel treatments and (4) tracking of LC survival and mortality outcomes by the hospital. Finland has the lowest access to computed tomography (CT) from primary care, longest waiting times in primary care, and lacks a national outcome tracking system. Some medical doctors in Finland and Iceland highlighted observed limitations in specific cases involving access to neoadjuvant immunotherapy and chemotherapy. Interpretation: Several factors unrelated to specialized LC care are likely contributing to poorer 5-year survival rates for LC in Finland. These findings may be applicable to other healthcare systems as well.
- Open Access
- 11 May 2023
- Published by Elsevier in Clinical Lung Cancer
- Vol. 24 (6) , 507-518
KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry
- 11 May 2023
- Published by Elsevier in Clinical Lung Cancer
- Vol. 24 (6) , 507-518
Open AccessKRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry
- Open Access
Association between obstructive sleep apnoea and cancer: a cross-sectional, population-based study of the DISCOVERY cohort
Objectives: Nocturnal hypoxia in obstructive sleep apnoea (OSA) is a potential risk factor for cancer. We aimed to investigate the association between OSA measures and cancer prevalence in a large national patient cohort. Design: Cross-sectional study. Settings: 44 sleep centres in Sweden. Participants: 62 811 patients from the Swedish registry for positive airway pressure (PAP) treatment in OSA, linked to the national cancer registry and national socioeconomic data (the course of DIsease in patients reported to Swedish CPAP, Oxygen and VEntilator RegistrY cohort). Outcome measures: After propensity score matching for relevant confounders (anthropometric data, comorbidities, socioeconomic status, smoking prevalence), sleep apnoea severity, measured as Apnoea-Hypopnoea Index (AHI) or Oxygen Desaturation Index (ODI), were compared between those with and without cancer diagnosis up to 5 years prior to PAP initiation. Subgroup analysis for cancer subtype was performed. Results: OSA patients with cancer (n=2093) (29.8% females, age 65.3 (SD 10.1) years, body mass index 30 (IQR 27–34) kg/m 2 ) had higher median AHI (n/hour) (32 (IQR 20–50) vs 30 (IQR 19–45), n/hour, p=0.002) and median ODI (n/hour) (28 (IQR 17–46) vs 26 (IQR 16–41), p<0.001) when compared with matched OSA patients without cancer. In subgroup analysis, ODI was significantly higher in OSA patients with lung cancer (N=57; 38 (21–61) vs 27 (16-43), p=0.012)), prostate cancer (N=617; 28 (17–46) vs 24, (16–39)p=0.005) and malignant melanoma (N=170; 32 (17–46) vs 25 (14–41),p=0.015). Conclusions: OSA mediated intermittent hypoxia was independently associated with cancer prevalence in this large, national cohort. Future longitudinal studies are warranted to study the potential protective influence of OSA treatment on cancer incidence.
Open AccessAssociation between obstructive sleep apnoea and cancer: a cross-sectional, population-based study of the DISCOVERY cohort
Objectives: Nocturnal hypoxia in obstructive sleep apnoea (OSA) is a potential risk factor for cancer. We aimed to investigate the association between OSA measures and cancer prevalence in a large national patient cohort. Design: Cross-sectional study. Settings: 44 sleep centres in Sweden. Participants: 62 811 patients from the Swedish registry for positive airway pressure (PAP) treatment in OSA, linked to the national cancer registry and national socioeconomic data (the course of DIsease in patients reported to Swedish CPAP, Oxygen and VEntilator RegistrY cohort). Outcome measures: After propensity score matching for relevant confounders (anthropometric data, comorbidities, socioeconomic status, smoking prevalence), sleep apnoea severity, measured as Apnoea-Hypopnoea Index (AHI) or Oxygen Desaturation Index (ODI), were compared between those with and without cancer diagnosis up to 5 years prior to PAP initiation. Subgroup analysis for cancer subtype was performed. Results: OSA patients with cancer (n=2093) (29.8% females, age 65.3 (SD 10.1) years, body mass index 30 (IQR 27–34) kg/m 2 ) had higher median AHI (n/hour) (32 (IQR 20–50) vs 30 (IQR 19–45), n/hour, p=0.002) and median ODI (n/hour) (28 (IQR 17–46) vs 26 (IQR 16–41), p<0.001) when compared with matched OSA patients without cancer. In subgroup analysis, ODI was significantly higher in OSA patients with lung cancer (N=57; 38 (21–61) vs 27 (16-43), p=0.012)), prostate cancer (N=617; 28 (17–46) vs 24, (16–39)p=0.005) and malignant melanoma (N=170; 32 (17–46) vs 25 (14–41),p=0.015). Conclusions: OSA mediated intermittent hypoxia was independently associated with cancer prevalence in this large, national cohort. Future longitudinal studies are warranted to study the potential protective influence of OSA treatment on cancer incidence.
- Open Access
- 24 February 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 185, 40-52
Spatial immunophenotyping of the tumour microenvironment in non–small cell lung cancer
- 24 February 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 185, 40-52
Open AccessSpatial immunophenotyping of the tumour microenvironment in non–small cell lung cancer
- Open Access
- 15 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0278706
Patterns of care and outcomes in immigrants with non-small cell lung cancer. A population-based study (Sweden)
Objectives: While studies have found lower cancer risks and better cancer survival in immigrant populations, it is debated whether cancer care is offered on equal terms to all residents regardless of background. Our aim was to study patterns of care and outcomes in immigrants in a country with a tax-financed universal health care system. Material and methods: We used a population-based database to compare clinical presentation, management and mortality between Swedish-born and immigrant patients with non-small cell lung cancer (NSCLC). Analyses were adjusted for potential confounders. Results: We identified 40,075 patients diagnosed with NSCLC of which 84% were born in Sweden, 7% in Nordic and 9% in Non-Nordic countries. Non-Nordic immigrants were to a higher extent male, smokers, younger at diagnosis, had a better performance status and a higher educational level. No differences were seen regarding comorbidity burden or stage at diagnosis. Non-Nordic immigrants more often underwent positron emission tomography (PET) (aHR 1.32; 95% CI 1.19–1.45) and were more often discussed in a multidisciplinary team setting (aHR 1.30; 95% CI 1.17–1.44). There were no differences in treatment modalities following adjustment for age, with the exception of concurrent chemoradiotherapy in stage IIIA disease which was more common in Non-Nordic immigrants (aOR 1.34; 95% CI 1.03–1.74). Both overall and cause specific survival in non-metastatic disease were higher among Non-Nordic immigrants. Overall mortality in stage I-II: HR 0.81; 95% CI 0.73–0.90 and stage IIIA: HR 0.75; 95% CI 0.65–0.86. Following full adjustments, cause-specific mortality in stage I-II was aHR 0.86, 95% CI 0.75–0.98. Conclusion: Taken together, only minor differences in management and outcomes were observed between Swedish-born and immigrant patients. We conclude that lung cancer care is offered on equal terms. If anything, outcomes were better in Non-Nordic immigrants with early stage NSCLC.
- 15 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0278706
Open AccessPatterns of care and outcomes in immigrants with non-small cell lung cancer. A population-based study (Sweden)
Objectives: While studies have found lower cancer risks and better cancer survival in immigrant populations, it is debated whether cancer care is offered on equal terms to all residents regardless of background. Our aim was to study patterns of care and outcomes in immigrants in a country with a tax-financed universal health care system. Material and methods: We used a population-based database to compare clinical presentation, management and mortality between Swedish-born and immigrant patients with non-small cell lung cancer (NSCLC). Analyses were adjusted for potential confounders. Results: We identified 40,075 patients diagnosed with NSCLC of which 84% were born in Sweden, 7% in Nordic and 9% in Non-Nordic countries. Non-Nordic immigrants were to a higher extent male, smokers, younger at diagnosis, had a better performance status and a higher educational level. No differences were seen regarding comorbidity burden or stage at diagnosis. Non-Nordic immigrants more often underwent positron emission tomography (PET) (aHR 1.32; 95% CI 1.19–1.45) and were more often discussed in a multidisciplinary team setting (aHR 1.30; 95% CI 1.17–1.44). There were no differences in treatment modalities following adjustment for age, with the exception of concurrent chemoradiotherapy in stage IIIA disease which was more common in Non-Nordic immigrants (aOR 1.34; 95% CI 1.03–1.74). Both overall and cause specific survival in non-metastatic disease were higher among Non-Nordic immigrants. Overall mortality in stage I-II: HR 0.81; 95% CI 0.73–0.90 and stage IIIA: HR 0.75; 95% CI 0.65–0.86. Following full adjustments, cause-specific mortality in stage I-II was aHR 0.86, 95% CI 0.75–0.98. Conclusion: Taken together, only minor differences in management and outcomes were observed between Swedish-born and immigrant patients. We conclude that lung cancer care is offered on equal terms. If anything, outcomes were better in Non-Nordic immigrants with early stage NSCLC.
- 11 January 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (3) , 320
Reply to Assoc. Prof. Kocak
We thank Kocak for the interest in our work (Kocak. Letter to the Editor Acta Oncologica 2021). We agree that BMI is a factor of importance that may influence cancer outcomes since both underweight...
- 11 January 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (3) , 320
Reply to Assoc. Prof. Kocak
We thank Kocak for the interest in our work (Kocak. Letter to the Editor Acta Oncologica 2021). We agree that BMI is a factor of importance that may influence cancer outcomes since both underweight...